Search
Incadronic acid
go.drugbank.com/drugs/DB06255ExperimentalIncadronate, or YM-175,[A202769] is a nitrogen containing bisphosphonate.
Talizumab
go.drugbank.com/drugs/DB05797ExperimentalTNX-901 is a therapeutic monoclonal antibodies designed to address significant unmet medical needs in the areas of asthma, allergy, inflammation and other diseases affecting the human immune system.
Eletriptan
go.drugbank.com/drugs/DB00216ApprovedInvestigationalEletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.
Products: ELETRIPTAN DOC GENERICISNS-314
go.drugbank.com/drugs/DB06134InvestigationalSNS-314 is a potent and selective inhibitor of Aurora kinases A, B, and C. … SNS-314 inhibits tumor growth in a variety of preclinical models, and it is now being tested in single agent Phase 1 studies in patients with advanced solid tumours.
Efavaleukin alfa
go.drugbank.com/drugs/DB16149InvestigationalEfavaleukin alfa is a fusion protein consisting of interleukin mutein fused to the C-terminus of an immunoglobulin G Fc domain by way of a G4S linker. … It is under investigation in clinical trial NCT03422627 (Safety and Efficacy of AMG 592 in Subjects With Steroid Refractory Chronic Graft Versus Host Disease).
Synonyms: Fc il-2 mutein fusion protein (amg-592)Pipendoxifene
go.drugbank.com/drugs/DB05414InvestigationalPipendoxifene is a new 2-phenyl indole selective estrogen receptor modulators (SERM )that exhibits an excellent preclinical pharmacological profile and was selected for further development as a treatment … ER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer.
Glisoxepide
go.drugbank.com/drugs/DB01289InvestigationalGlisoxepide is one of the sulphonamide-derived oral antidiabetic drugs. It inhibits the uptake of bile acids into isolated rat hepatocytes. However it inhibits taurocholate uptake only in the absence of sodium ions. Glisoxepide uptake co...
Covax-19™
go.drugbank.com/drugs/DB15846InvestigationalCovax-19™, a protein-based vaccine, was developed through partnership between APC and Vaxine. It uses an insect-cell-produced recombinant SARS-CoV-2 spike protein and Vaxine’s adjuvant, Advax-SM. … As of June 2020, the vaccine is in Phase 1 trials to evaluate safety and immune responses (NCT04428073).